Genfit S.A.
GNFT
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.10
Price+2.52%
$0.15
1Y
Price
Market Cap
$303.760m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.+2.7%
EBITDA Margin-28.0%
Net Profit Margin-87.7%
Free Cash Flow Margin+2.7%
EBITDA Margin-28.0%
Net Profit Margin-87.7%
Free Cash Flow MarginRevenue
$116.802m
+74.3%
1y CAGR+83.5%
3y CAGR+43.9%
5y CAGREarnings
-$16.489m
-1194.2%
1y CAGR-370.2%
3y CAGR-311.5%
5y CAGREPS
-$0.44
-1566.7%
1y CAGR-494.1%
3y CAGR-405.3%
5y CAGRBook Value
$52.472m
$216.683m
Assets$164.211m
Liabilities$138.913m
DebtDebt to Assets
64.1%
-99.1x
Debt to EBITDAFree Cash Flow
-$47.166m
-431.7%
1y CAGR-95.6%
3y CAGR-115.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company